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Abstract. We present a 44-year-old man from a rural community in northern Ecuador who worked on a cattle farm
where he was involved with primary veterinary care, including assistance during births (or calving) and placenta retention
and artificial insemination, with minimal precautions. In September of 2009, quite abruptly, he developed asthenia and
hypersomnia without any apparent cause or symptoms like fever, chills, or night sweats. On November 14, 2009,
he suffered from pain and edema in the right testicle that coincided with pain in the abdomen. Clinical, serological, and
bacteriological investigations confirmed the first case of unilateral orchitis in man in Ecuador caused by Brucella abortus
biovar 1. Because brucellosis is a neglected disease, special attention should be given to it in the training of medical and
veterinary students.
INTRODUCTION
Brucellosis is a bacterial infection with severe repercussions
on human and animal health, causing heavy losses worldwide.1
In man, it can start as an acute disease with recurrent fever,
sweating, general discomfort, headache, muscle pain, and
arthritis. The infection is acquired through direct or indirect
contact with infectious material from animal origin (i.e.,
aborted fetuses, placentas, and vaginal secretions) as well as
accidental inoculation of vaccine, inhalation of aerosols, or
consumption of non-pasteurized dairy products (mostly affect-
ing slaughterhouse or laboratory staff).2
The frequency of human infections is directly related to the
prevalence in animal reservoirs.3 In countries where adequate
control or eradication programs are implemented, this zoo-
nosis is a professional hazard, whereas in developing countries,
the entire population is at risk, including tourists or other visi-
tors of contaminated ranches.4
Complications such as spondilytis, arthritis, hepato-
splenomegaly, and endocarditis are often observed in humans
with genitourinary inflammations (epididymitis, orchitis, and
prostatitis) reported in 2–20% of positive cases.5 Brucella
melitensis is reported to be the most pathogenic species in
man and responsible for most of the clinical cases in man.
According to official reports, the annual incidence of
human brucellosis in Ecuador remains rather low (i.e.,
between 1990 and 2007, it affected no more than 0.21 per
100,000 persons),6 whereas in the same time span, in Carchi
(the province where the present case has been described),
four positive cases were detected (0.62 per 100,000 persons).6
In the absence of an official reference laboratory in Ecuador,
routine isolation and biotyping of Brucella spp. are not done;
for this reason, the existence of possible reservoirs remained
completely unknown.
In contrast, preliminary studies by the International Center
for Zoonosis (CIZ) suggest that the seroprevalence of brucel-
losis in man can be around 2% in the northwestern provinces
of Ecuador. The main risk factors are the consumption of
boiled milk (odds ratio [OR] = 4.69, confidence interval [CI] =
1.45–15.18) or raw milk (OR = 5.13, CI = 1.52–17.29) and
contact with fetal and placental tissue (OR = 2.10, CI = 1.02–
4.33) from cattle (Ron-Roma´n J and others, unpublished data).
CASE REPORT
A male patient (44 years old, married, and born and living
in Cuaspud, a rural community in Huaca canton, Carchi prov-
ince, in the north of Ecuador) worked as a cattle farm laborer
for the last 3 years. As such, he was actively involved with
primary veterinary healthcare, including assistance during
births and placenta retention and artificial insemination in
the cantons Huaca, Montufar, Bolı´var, and Tulca´n in Carchi
province with minimal hygienic precautions.
In September of 2009, quite abruptly, he developed asthenia
and hypersomnia without any apparent cause or symptoms
like fever, chills, or night sweats. On November 14, 2009, he
suffered from pain and oedema in the right testicle and abdom-
inal pain. He consulted a general practitioner in the city of
Tulca´n who empirically prescribed 75 mg sodium diclofenac
(during 7 days), 10 mg sodium naproxen (during 7 days), and
200 mg cefpodoxime (during 7 days). This treatment, however,
brought no relief, and as suggested by a veterinarian, a brucel-
losis agglutination test (Febrile Antigen Agglutination Test;
Becton Dickinson, Sparks, MD) was performed in a private
laboratory in Tulca´n. This test showed a positive titer of 1/320
(cutoff ³ 1/160) for Brucella spp. On November 22, he started
to suffer from lumbalgia, testicular edema, and generalized asthe-
nia. During this period, he had unprotected sex with his wife.
On November 23, he came to the CIZ of Central University
of Ecuador with the diagnosis of unilateral right orchitis,
lumbosacral pains, general asthenia, and positive diagnosis
of brucellosis by the Febrile Antigen Agglutination Test
(Becton Dickinson).
At CIZ, two serological tests showed these results: fast
agglutination plate assay was Rose Bengal (RB) positive (++),
and Wright’s slow agglutination test with ethylenediamine-
tetraacetic acid (SAT-EDTA) was positive (1,280 international
units of agglutination [IAU], dilution 1/800, cutoff ³ 1/25). On
November 26, a blood culture (4 days incubation; Bactec Sys-
tem) was positive for the presence of Brucella spp. in Hospital
Vozandes Quito (HVQ).
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On December 3 in the outpatient clinic of the same hospi-
tal, the medical staff opted for the treatment regimen
recommended by the World Health Organization7 of doxy-
cycline (100 mg, BID) for 6 weeks and gentamicin (320 mg
intravenously daily) for 10 days. Vital signs seemed to be
normal: blood pressure (BP) = 110/60 mmHg, pulse (P) =
71/minute, oral temperature (OT) = 37°C, and weight = 57.5 kg;
on rectal examination, no evidence of prostatitis was observed.
High values for C-reactive protein (56.9 mg/L; normal values
are between 0.00 and 5.00 mg/L) indicated an inflammatory
process; hematological, biochemical, and serological results
are presented in Table 1.
In the laboratory for microbiology of CIZ, culture of the
patient’s semen in Farrell’s medium (Columbia Blood Agar
Base CM0331 [Oxoid] + horse serum [reference 16050–130;
Gibco] + modified Brucella Selective Supplement SR0209E
[Oxoid]) isolated Brucella sp. Subsequently, both strains
from blood (Ec-CIZ-Hum-6) and semen (Ec-CIZ-Hum-7)
were typified as B. abortus biovar 1 (field strain) by biochem-
ical assays (Table 2) and Abortus, Melitensis, Ovis and Suis
(AMOS)-polymerase chain reaction (Figure 1).8–10
Two blood samples (taken on 12/3/2009 and 3/26/2010)
of the patient’s wife yielded negative results in the RB and
SAT-EDTA assays; hence, no sexual transmission occurred.
On December 17 at a clinical follow-up in the hospital, the
patient’s status was improved, with receding orchitis, low
back pain, and asthenia. Vital signs were stable (BP = 100/
70 mmHg, P = 78/minute, OT = 37°C, and weight = 61.5 kg).
Immunological assays showed the presence of Brucella sp. anti-
bodies (RB +++ and SAT-EDTA = 1,280 IAU); Brucella sp.
remained persistent in the blood circulation as shown by
blood culture. Additional results are presented in Table 1.
On January 8, 2010, a decrease in circulating immunoglobu-
lin M (IgM) was shown by SAT-EDTA (400 IAU), but the
RB assay remained highly positive (+++). Additional values
are presented in Table 1. The third visit showed a complete
recovery of the patient: BP = 120/90 mmHg, P = 67/minute,
OT = 36.5°C, and weight = 60 kg. The patient was declared
to be cured, and a monthly serological follow-up to detect
relapses was recommended.
As presented in Table 3, the results of the serological assays
showed a fast decline of IgM levels (as detected by SAT-
EDTA), whereas the levels of IgG (by RB) remained high.
In August of 2010, the patient reported a mild pain in the
lumbosacral joint that deteriorated in time. Based on a clini-
cal examination and laboratory results (Table 3) showing a
steep rise in IgM and IgG (i.e., by SAT-EDTA on 7/14/2010
and much later on 12/1/2010 by RB), the infectious diseases
Table 1
Case report of a patient with brucellosis-related epididymo-orchitis: Hematological and biochemical values
Results
Units Reference range12/3/2009 12/17/2009 1/8/2010
Sedimentation rate 24* 5 ND mm/hour 0–20
Leukocytes 7.93 5.22 5.06 K/mL 4.80–10.80
Neutrophils 52.0 41.2* 40.9* % 43.0–65.0
Lymphocytes 35.3 50.6* 50.0* % 20.5–45.5
Monocytes 12.0* 6.3 7.1 % 1.9–9.0
Eosinophils 0.4* 1.1 1.4 % 1.0–5.0
Basophils 0.3 0.8 0.6 % 0.2–1.0
Erythrocytes 5.36 5.52 5.51 M/mL 4.5–6.0
Hemoglobin 16.0 16.5 16.4 g/dL 14.0–18.0
Hematocrit 47.3 47.7 48.6 % 41.0–51.0
Mean corpuscular volume 88.2 86.4 88.2 fL 80.0–90.0
Mean corpuscular HB 29.9 29.9 29.8 pg 27.0–31.0
Mean corpuscular HB concentration 33.8 34.6 33.7 g/dL 32–36
Distribution width RDW SD 42.8 41.6 43.0 fL 37.0–54.0
Distribution width RDW CV 14.1 13.9 14.0 % 11.5–15.5
Platelets 308 282 252 K/mL 100–500
Mean platelet volume 8.7 8.4 8.9 fL 7.2–9.5
C-reactive protein 56.9* 0.66 0.36 mg/L 0.00–5.00
Creatinine 0.86 0.98 ND mg/dL 0.70–1.20
*Values outside reference range.
ND = not done; HB = hemoglobin; RDW = red cell distribution width; SD = standard deviation; CV = coefficient variation.
Table 2









































B2* + + + − − − − + −
B9† + − + + + + + − +
B1 + +‡ + − − + + + −
*Control B. abortus biovar 2.
†Control B. abortus biovar 9.
‡Positive for the most of the strains.
EC-CIZ-Hum-6 and -7 are the Brucella isolates from the patient.
ORCHITIS IN MAN CAUSED BY B. ABORTUS BIOVAR 1 IN ECUADOR 525
specialist of HVQ decided to start the treatment again to
treat a possible relapse.
On November 7, 2010, the following treatment was used:
doxycycline (100 mg every 12 hours) for 6 weeks plus genta-
micin (320 mg daily intravenously) for 2 weeks. At that time,
blood and semen cultures were negative for Brucella sp.
DISCUSSION
The official reports concerning the surveillance, control,
and eradication of brucellosis in Ecuador state the limited
importance of this zoonosis,6 and as such, these reports are
accepted in the international literature11; however, they seem
to be far from reality. Studies performed by the CIZ show
more realistic numbers of cases that are not only in persons
living or working in high-risk conditions (Ron-Roma´n J and
others, unpublished data).
Epididymo-orchitis is frequently observed in regions where
B. melitensis is endemic,12 and it has been described in 2–20%
of the infected patients12–14 (mostly younger patients).12,14,15
However, the present study is the first report in Ecuador with
B. abortus as the causative agent.
Usually, brucellosis-related epididymo-orchitis is unilat-
eral,12,16–19 but bilateral infections have been reported.20,21
As in the present case, the majority of cases (53–69%) were
confirmed by positive blood cultures.13
Isolation of Brucella by epididymal aspiration was
performed in 6.7% of the patients with epididymo-orchitis22;
in the present study, B. abortus was isolated from semen, which
warranted the possibility of sexual transmission, but paired
serology taken from his wife with an interval of 16 weeks
remained negative by RB and SAT-EDTA. The isolation of
B. melitensis in semen from a patient with epididymo-orchitis
has been reported23; also, Brucella sp. has been isolated from
blood culture.24
Several works have promoted leucocytosis as an indica-
tor to differentiate epididymo-orchitis caused by Brucella
spp.14,15,18,20,25–27from non-specific orchitis, but it was not
observed in this case. In non-specific orchitis, signs of inflam-
mation are very clear (i.e., dermatitis of the scrotal skin). In
Brucella spp.-induced orchitis, the fever is undulating and
lower than in nonspecific orchitis; also, in the present case,
the patient never reported fever or chills.28
Although the final diagnosis of brucellosis is based on the
isolation of the causal agent, usually from blood samples or
other bodily fluids, the use of standardized immunodiagnostic
assays would be a great contribution to the diagnosis. Cases of
brucellosis confirmed by blood culture with negative serolog-
ical results have been reported, albeit they are rare.29,30
When bacterial isolation is negative but serological results
are positive or suspected, this zoonosis has to be taken into
account, even more so when there is a history of risk, such as
contact with natural carriers, dubious hygienic standards, living
in an endemic area, or symptoms associated with brucellosis.
In endemic regions, the slightest suspicion should be suffi-
cient to start treatment in anticipation of the confirmation by
laboratory tests.13 Therefore, a detailed anamnesis together
with a correct risk assessment is of the utmost importance to
underpin the diagnosis and specific treatment of epididymo-
orchitis, and it will help to avoid complications such as testic-
ular abscesses or atrophy leading to infertility.31–33 In patients
with epididymo-orchitis, the differential diagnosis should
include brucellosis when living in an endemic region such as
Ecuador, especially when these patients belong to a high-risk
population. In this respect, it is interesting to note that, in
2008, epididymo-orchitis was reported in 983,286 hospitalized
patients in Ecuador, but only 369 (0.037%) cases were ascribed
to brucellosis (diagnostic codes N.45.0–N.45.9 according to
International Statistical Classification of Diseases and Related
Health Problems).34 However, the 369 cases, provisionally
attributed to brucellosis, were not confirmed by the isolation
of the causal agent because of the lack of a diagnostic strategy
and laboratory infrastructure for this zoonosis.
Given the intracellular localization of Brucella spp. mostly
in the reticulo endotelial cells, the choices of the antibiotic,
its dose, and duration of the treatment are crucial. The com-
bined use of antibiotics for the treatment of brucellosis is
often recommended, specifically when complications like
epididymo-orchitis are involved, and it might help to reduce
the chances of relapses.35 The synergy of several antibiotics
(doxycycline, rifampicin, and streptomycin) has shown effi-
cacy in the treatment of this zoonosis.17
Table 3
Case report of a patient with brucellosis-related epididymo-orchitis:
Results of the serological assays
Sample number Date RB SAT-EDTA (IAU)
1 11/23/2009 ++ 1,280
2 12/17/2009 ++ 960
3 1/8/2010 ++ 480
4 2/14/2010 + 160
5 3/26/2010 + 120
6 4/24/2010 + 120
7 5/31/2010 + 100
8 7/14/2010 + 200
9 8/17/2010 + 240
10 9/21/2010 + 400
11 10/18/2010 + 240
12 12/1/2010 ++ 200
13 1/14/2011 ++ 200
14 2/11/2011 + 100
15 3/17/2011 + 100
16 4/27/2011 + 100
17 6/6/2011 + 80
18 7/14/2011 + 60
19 8/11/2011 + 60
20 10/21/2011 + 50
21 12/12/2011 + 30
IAU = international units of agglutination; RB = Rose Bengal test; SAT-EDTA =
Wright’s slow agglutination test with EDTA.
Figure 1. Case report of a patient with brucellosis-related
epididymo-orchitis: AMOS-polymerase chain reaction results. CN =
negative control; CP = positive control; H-19 = human sample 19 (Ec-
CIZ-Hum-7); H-21 = human sample 21 (Ec-CIZ-Hum-6); MP =
molecular weight marker. *Samples from additional studies at CIZ.
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Relapse of uncomplicated cases has been reported in 5–10%
of cases,36 and it generally occurs weeks or months after the
end of the treatment; it should be confirmed by the isolation of
Brucella from blood or other bodily fluids or tissues.37 How-
ever, in the present case, thanks to the continuous serological
follow-up, the event of a possible relapse could be anticipated.
As such, a complementary treatment was justified, thus
avoiding septicemia and clinical complications.
For RB, the intensity of reaction was expressed as negative
(–; absence of reaction) or + to ++++ (degree of agglutina-
tion), which a posteriori enables comparison with other quan-
titative assays such as i-enzyme–linked immunosorbent assay.
A possible relapse could not be confirmed by isolation of
the causal agent (i.e., a negative blood and semen culture
until 10/7/2010), but given the history of orchitis, it was
decided to start a second treatment to minimize the risk for a
relapse or development of a chronic localized brucellosis.
Furthermore, the results of the SAT-EDTA assay (Table 3)
and the symptoms reported by the patient underpinned the
decision for a second treatment. However, despite the detec-
tion of antibodies on 7/14/2010, at that time, the medical
specialist did not consider this result to be a sufficient crite-
rion to start a second treatment. It only began when the pain
in the lumbosacral region started to rise combined with an
increase of antibodies, mainly detected by SAT-EDTA.
The observations made during the follow-up of the present
case emphasize the need to accurately identify the causal agent
of the disease and not rely solely on symptomatic treatment.
As pointed out in previous studies by the CIZ, brucellosis is an
important zoonosis in Ecuador; therefore, it is essential that, in
primary healthcare, the clinical and serological tools to diag-
nose this infection should be available. In addition, because it
is a neglected disease, special attention should be given to it in
the training of medical and veterinary students.
To minimize as much as possible the risk for the human
population to contract brucellosis in Ecuador, efforts should
be made to control (eradicate) brucellosis in its natural reser-
voirs, and therefore, a solid control (eradication) program is
needed. In anticipation of this program, it is necessary to
implement an education program, covering topics related to
the transmission, prevention, control, and diagnosis of brucel-
losis in man and animals, at least for the population at risk
and its medical staff. Finally, we want to emphasize that no
control or eradication program for the brucellosis in Ecuador
will bring satisfactory results at the desired time without the
compromise and joint work between the different actors at
national level. Medical doctors and veterinarians should focus
and shore up the One Health initiative.
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